Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

被引：0

作者：

U Platzbecker

F Braulke

A Kündgen

K Götze

G Bug

C Schönefeldt

K Shirneshan

C Röllig

M Bornhäuser

R Naumann

J Neesen

A Giagounidis

W-K Hofmann

G Ehninger

U Germing

D Haase

M Wermke

机构：

[1] Medical Clinic and Polyclinic I,Department of Hematology and Oncology

[2] University Hospital,Department of Hematology and Oncology

[3] Technical University Dresden,undefined

[4] University Hospital,undefined

[5] University Göttingen,undefined

[6] University Hospital,undefined

[7] Heinrich Heine University Düsseldorf,undefined

[8] Medical Clinic,undefined

[9] University Hospital,undefined

[10] Technical University Munich,undefined

[11] Clinic of Hematology and Oncology,undefined

[12] J.W. Goethe University Hospital,undefined

[13] Stiftungsklinikum Mittelrhein,undefined

[14] Institute of Medical Genetics,undefined

[15] Medical University Vienna,undefined

[16] St Johannes Hospital,undefined

[17] Clinic of Hematology and Oncology,undefined

[18] Hospital of the Ruprecht Karls University,undefined

来源：

Leukemia | 2013年 / 27卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1403 / 1407

页数：4

共 50 条

[1] Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
Platzbecker, U.
Braulke, F.
Kuendgen, A.
Goetze, K.
Bug, G.
Schoenefeldt, C.
Shirneshan, K.
Roellig, C.
Bornhaeuser, M.
Naumann, R.
Neesen, J.
Giagounidis, A.
Hofmann, W-K
Ehninger, G.
Germing, U.
Haase, D.
Wermke, M.
LEUKEMIA, 2013, 27 (06) : 1403 - 1407
[2] “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
Bengt Rasmussen
Gudrun Göhring
Elsa Bernard
Lars Nilsson
Magnus Tobiasson
Martin Jädersten
Hege Garelius
Ingunn Dybedal
Kirsten Grønbaek
Elisabeth Ejerblad
Fryderyk Lorenz
Max Flogegård
Claus Werenberg Marcher
Annette Öster Fernström
Lucia Cavelier
Elli Papaemmanuil
Freja Ebeling
Astrid Olsnes Kittang
Jan Maxwell Nørgaard
Leonie Saft
Lars Möllgård
Eva Hellström-Lindberg
Leukemia, 2022, 36 : 1436 - 1439
[3] Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)
Rasmussen, Bengt
Gohring, Gudrun
Bernard, Elsa
Nilsson, Lars
Tobiasson, Magnus
Jadersten, Martin
Garelius, Hege
Dybedal, Ingunn
Gronbaek, Kirsten
Ejerblad, Elisabeth
Lorenz, Fryderyk
Flogegard, Max
Marcher, Claus Werenberg
oster Fernstrom, Annette
Cavelier, Lucia
Papaemmanuil, Elli
Ebeling, Freja
Kittang, Astrid Olsnes
Norgaard, Jan Maxwell
Saft, Leonie
Mollgard, Lars
Hellstrom-Lindberg, Eva
LEUKEMIA, 2022, 36 (05) : 1436 - 1439
[4] Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Zeidan, Amer M.
Gore, Steven D.
Komrokji, Rami S.
EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (03) : 251 - 254
[5] Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53-Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes
Platzbecker, Uwe
Braulke, Friederike
Kuendgen, Andrea
Goetze, Katharina S.
Bug, Gesine
Shirneshan, Katayoon
Roellig, Christoph
Bornhaeuser, Martin
Naumann, Ralph
Neesen, Juergen
Giagounidis, Aristoteles
Hofmann, Wolf-Karsten
Ehninger, Gerhard
Germing, Ulrich
Haase, Detlef
Wermke, Martin
BLOOD, 2012, 120 (21)
[6] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
Sekeres, Mikkael A.
List, Alan F.
Cuthbertson, David
Paquette, Ronald
Ganetsky, Rebecca
Latham, Deborah
Paulic, Katarina
Afable, Manuel
Saba, Hussain I.
Loughran, Thomas P., Jr.
Maciejewski, Jaroslaw P.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2253 - 2258
[7] Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein, Elan
Weber, Urs M.
Gore, Steven
EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (03) : 233 - 239
[8] Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
Sekeres, Mikkael A.
Tiu, Ramon V.
Komrokji, Rami
Lancet, Jeffrey
Advani, Anjali S.
Afable, Manuel
Englehaupt, Ricki
Juersivich, Joyce
Cuthbertson, David
Paleveda, Jennifer
Tabarroki, Ali
Visconte, Valeria
Makishima, Hideki
Jerez, Andres
Paquette, Ronald
List, Alan F.
Maciejewski, Jaroslaw P.
BLOOD, 2012, 120 (25) : 4945 - 4951
[9] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
DiNardo, Courtney D.
Daver, Naval
Jabbour, Elias
Kadia, Tapan
Borthakur, Gautam
Konopleva, Marina
Pemmaraju, Naveen
Yang, Hui
Wei, Yue
Wierda, William G.
Bueso-Ramos, Carlos E.
Patel, Keyur P.
Cortes, Jorge E.
Ravandi, Farhad
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD, 2014, 124 (21)
[10] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Sekeres, Mikkael A.
List, Alan F.
Cuthbertson, David
Paquette, Ronald
Latham, Deborah
Afable, Manual
Paulic, Katarina
Loughran, Thomas P., Jr.
Maciejewski, Jaroslaw P.
BLOOD, 2008, 112 (11) : 88 - 89

← 1 2 3 4 5 →